|
Seaside Therapeutics is creating new drug treatments to correct or improve the course of
fragile X syndrome, autism and other disorders of
brain development. We are dedicated to translating breakthrough discoveries in neurobiology into therapeutics that improve the lives of patients and
their families. |
 |
Artwork by: Giant Steps, CT, School Project 2008
The artwork showcased on our website was created by children and adults with disorders of brain development. We'd like to thank these exceptional artists and the M.I.N.D. Institute at the University of California-Davis, where many of these pieces of artwork are on permanent display.
|
|
 |
February 26, 2009
Letter from Seaside Therapeutics' Chief Executive Officer Dr. Randy Carpenter
September 30, 2008
Seaside receives $2.59M NIH Grant “Development of mGluR5 Antagonists to treat Fragile X Syndrome and Autism” (3U01 MH078270- 02S1). Grant funded by National Institute of Child Health Development (NICHD) and the Best Pharmaceutical for
Children’s Act
September 15, 2008
Seaside Therapeutics Appoints Dr. Paul Wang to the Key Position of Vice President, Clinical Development
|
